Mechanisms for the selective actions of vitamin D analogs

Vitamin D

Volumn , Issue , 2011, Pages 1437-1459

  Brown, Alex J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861577905     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10075-7     Document Type: Chapter

References (207)

1. Norman A.W. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006, 147:5542-5548.
2. Panda D.K., Miao D., Bolivar I., Li J., Huo R., Hendy G.N., et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J. Biol. Chem. 2004, 279:16754-16766.
3. Shiizaki K., Hatamura I., Imazeki I., Moriguchi Y., Sakaguchi T., Saji F., et al. Improvement of impaired calcium and skeletal homeostasis in vitamin D receptor knockout mice by a high dose of calcitriol and maxacalcitol. Bone 2009, 45:964-971.
4. Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K.J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J. Clin. Invest. 1984, 74:2136-2143.
5. Smith E.L., Pincus S.H., Donovan L., Holick M.F. A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasis. J. Am. Acad. Dermatol. 1988, 19:516-528.
6. Drezner M.K., Lyles K.W., Haussler M.R., Harrelson J.M. Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia. J. Clin. Invest. 1980, 66:1020-1032.
7. Eelen G., Gysemans C., Verlinden L., Vanoirbeek E., De Clercq P., Van Haver D., et al. Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs. Curr. Med. Chem. 2007, 14:1893-1910.
8. Brown A.J., Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol. Aspects Med. 2008, 29(6):433-452.
9. Pike J.W., Yamamoto H., Shevde N.K. Vitamin D receptor-mediated gene regulation mechanisms and current concepts of vitamin D analog selectivity. Adv. Ren. Replace. Ther. 2002, 9:168-174.
10. Brown A.J., Slatopolsky E. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:134-144.
11. Brown A.J., Ritter C.R., Finch J.L., Morrissey J., Martin K.J., Murayama E., et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J. Clin. Invest. 1989, 84:728-732.
12. Naveh-Many T., Silver J. Effects of calcitriol, 22-oxacalcitriol, and calcipotriol on serum calcium and parathyroid hormone gene expression. Endocrinology 1993, 133:2724-2728.
13. Hirata M., Endo K., Katsumata K., Ichikawa F., Kubodera N., Fukagawa M. A comparison between 1,25-dihydroxy-22-oxavitamin D3 and 1,25-dihydroxyvitamin D3 regarding suppression of parathyroid hormone and calcemic action. Nephol. Dial. Transplant. 2002, 17(Suppl. 10):41-45.
14. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am. J. Kidney. Dis. 1995, 26:852-860.
15. 2 decreases with duration of treatment. J. Am. Soc. Nephrol. 2000, 11:2088-2094.
16. 2 on calcium and phosphorus resorption in bone. J. Am. Soc. Nephrol. 1999, 10:980-985.
17. 3 on intestinal calcium and phosphate transport. J. Lab. Clin. Med. 2002, 139:279-284.
18. Coyne D.W., Grieff M., Ahya S.N., Giles K., Norwood K., Slatopolsky E. Differential effects of acute administration of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am. J. Kidney. Dis. 2002, 40:1283-1288.
19. Fan S.L.S., Schroeder N.J., Calverley M.J., Burrin J.M., Makin H.L.J., Cunningham J. Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol(2). Nephol. Dial. Transplant. 2000, 15:1943-1949.
20. Hruby M., Urena P., Mannstadt M., Schmitt F., Lacour B., Drueke T.B. Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 1996, 11:1781-1786.
21. Plum L.A., Prahl J.M., Ma X., Sicinski R.R., Gowlugari S., Clagett-Dame M., et al. Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc. Natl. Acad. Sci. USA 2004, 101:6900-6904.
22. Slatopolsky E., Finch J.L., Brown A.J., Ritter C.S., Mizobuchi M., Plum L.A., et al. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism. J. Bone Miner. Res. 2007, 22:686-694.
23. Williams K.B., DeLuca H.F. 2-Methylene-19-nor-20(S)-1alpha-hydroxy-bishomopregnacalciferol [20(S)-2MbisP], an analog of vitamin D3 [1,25(OH)2D3], does not stimulate intestinal phosphate absorption at levels previously shown to suppress parathyroid hormone. Steroids 2008, 73:1277-1284.
24. Binderup L., Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem. Pharmacol. 1988, 37:889-895.
25. Kragballe K. Calcipotriol: a new drug for topical psoriasis treatment. Pharmacol. Toxicol. 1995, 77:241-246.
26. Matsunaga T., Yamamoto M., Mimura H., Ohta T., Kiyoki M., Ohba T., et al. 1,24(R)-dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. J. Dermatol. 1990, 17:135-142.
27. Morimoto S., Imanaka S., Koh E., Shiraishi T., Nabata T., Kitano S., et al. Comparison of the inhibitions of proliferation of normal and psoriatic fibroblasts by 1 alpha,25-dihydroxyvitamin D3 and synthetic analogues of vitamin D3 with an oxygen atom in their side chain. Biochem. Int. 1989, 19:1143-1149.
28. Endo K., Ichikawa F., Uchiyama Y., Katsumata K., Ohkawa H., Kumaki K., et al. Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-related peptide gene in vivo. J. Biol. Chem. 1994, 269:32693-32699.
29. Haq M., Kremer R., Goltzman D., Rabbani S.A. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J. Clin. Invest. 1993, 91:2416-2422.
30. Abe J., Nakano T., Nishii Y., Matsumoto T., Ogata E., Ikeda K. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991, 129:832-837.
31. Oikawa T., Yoshida Y., Shimamura M., Ashino-Fuse H., Iwaguchi T., Tominaga T. Antitumor effect of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer. Drugs 1991, 2:475-480.
32. Colston K.W., Chander S.K., Mackay A.G., Coombes R.C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem. Pharmacol. 1992, 44:693-702.
33. Colston K.W., Mackay A.G., James S.Y., Binderup L., Chander S., Coombes R.C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem. Pharmacol. 1992, 44:2273-2280.
34. Anzano M.A., Smith J.M., Uskokovic M.R., Peer C.W., Mullen L.T., Letterio J.J., et al. 1 Alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. Cancer Res. 1994, 54:1653-1656.
35. 5, a synthetic analog of vitamin D. Mutat. Res. 2003, 523-524:253-264.
36. Lee H.J., Paul S., Atalla N., Thomas P.E., Lin X., Yang I., et al. Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer. Prev. Res. (Phila Pa) 2008, 1:476-484.
37. 3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer. Res. 2003, 23:283-289.
38. Ghous Z., Akhter J., Pourgholami M.H., Morris D.L. Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer. Res. 2008, 28:3757-3761.
39. Lucia M.S., Anzano M.A., Slayter M.V., Anver M.R., Green D.M., Shrader M.W., et al. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue RO24-5531 for adrogen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer. Res. 1995, 55:5621-5627.
40. Schwartz G.G., Hill C.C., Oeler T.A., Becich M.J., Bahnson R.R. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 1995, 46:365-369.
41. Otoshi T., Iwata H., Kitano M., Nishizawa Y., Morii H., Yano Y., et al. Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analogue of 1 alpha. 25-dihydroxyvitamin D3 Carcinogenesis 1995, 16:2091-2097.
42. Wali R.K., Bissonnette M., Khare S., Hart J., Sitrin M.D., Brasitus T.A. 1 Alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 alpha,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis. Cancer. Res. 1995, 55:3050-3054.
43. 3 and its synthetic analog decrease tumor load in the Apc(min) mouse. Cancer. Res. 2002, 62:741-746.
44. Zhou J.Y., Norman A.W., Chen D.L., Sun G.W., Uskokovic M., Koeffler H.P. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. USA 1990, 87:3929-3932.
45. Prudencio J., Akutsu N., Benlimame N., Wang T., Bastien Y., Lin R., et al. Action of low calcemic 1a,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma. J. Natl. Cancer. Inst. 2001, 93:745-753.
46. Lee H.J., SO J.Y., Decastro A., Smolarek R., Paul S., Maehr H., Uskokovic M. Suh N Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J. Steroid Biochem. Mol. Biol. 2010, 121:408-412.
47. B. Filip, M. Milczarek, J. Wietrzyk, M. Chodynski, A. Kutner, Antitumor properties of (5E,7E) analogs of vitamin D(3). J. Steroid Biochem. Mol. Biol. 121 (2010) 399-402.
48. Abe J., Takita Y., Nakano T., Miyaura C., Suda T., Nishii Y. A synthetic analogue of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 1989, 124:2645-2647.
49. 3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 1994, 135:2818-2821.
50. Mathieu C., Waer M., Casteels K., Laureys J., Bouillon R. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 1995, 136:866-872.
51. 3 analog with reduced hypercalcemic activity. J. Invest. Dermatol. 2002, 119:1434-1442.
52. Zugel U., Steinmeyer A., May E., Lehmann M., Asadullah K. Immunomodulation by a novel, dissociated Vitamin D analogue. Exp. Dermatol. 2009, 18:619-627.
53. Adorini L., Penna G., Amuchastegui S., Cossetti C., Aquilano F., Mariani R., et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J. Steroid Biochem. Mol. Biol. 2007, 103:689-693.
54. Nishii Y., Sato K., Kobayashi T. The development of vitamin D3 analogues for the treatment of osteoporosis. Osteoporos. Int. 1993, 3:190-193.
55. Uchiyama Y., Higuchi Y., Takeda S., Masaki T., Shira-Ishi A., Sato K., et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002, 30:582-588.
56. Tanaka Y., Nakamura T., Nishida S., Suzuki K., Takeda S., Sato K., et al. Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J. Bone Min. Res. 1996, 11:325-336.
57. Peleg S., Uskokovic M., Ahene A., Vickery B., Avnur Z. Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology 2002, 143:1625-1636.
58. 3 selectively induced bone formation. Proc. Natl. Acad. Sci. USA 2002, 99:13487-13491.
59. Kittaka A., Hara H., Takano M., Sawada D., Arai M.A., Takagi K., et al. Synthesis and biological activities of 14-epi-MART-10 and 14-epi-MART-11: implications for cancer and osteoporosis treatment. Anticancer. Res. 2009, 29:3563-3569.
60. Sato M, Lu J, Iturria S, Stayrook KR, Burris LL, Zeng QQ, Schmidt A, Barr RJ, Montrose-Rafizadeh C, Bryant HU, Ma YL A non-secosteroidal vitamin D receptor ligand with improved therapeutic window of bone efficacy over hypercalcemia. J. Bone Miner. Res. 25 (6) (2010) 1326-1336.
61. Krisinger J., Strom M., Darwish H.D., Perlman K., Smith C., DeLuca H.F. Induction of calbindin-D 9k mRNA but not calcium transport in rat intestine by 1,25-dihydroxyvitamin D3 24-homologs. J. Biol. Chem. 1991, 266:1910-1913.
62. Wang Y.Z., Li H., Bruns M.E., Uskokovic M., Truitt G.A., Horst R., et al. Effect of 1,25,28-trihydroxyvitamin D2 and 1,24,25-trihydroxyvitamin D3 on intestinal calbindin-D9K mRNA and protein: is there a correlation with intestinal calcium transport?. J. Bone Min. Res. 1993, 8:1483-1490.
63. Elstner E., Lee Y.Y., Hashiya M., Pakkala S., Binderup L., Norman A.W., et al. 1 Alpha,25-dihydroxy-20-epi-vitamin D3: an extraordinarily potent inhibitor of leukemic cell growth in vitro. Blood 1994, 84:1960-1967.
64. Crofts L.A., Hancock M.S., Morrison N.A., Eisman J.A. Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc. Natl. Acad. Sci. USA 1998, 95:10529-10534.
65. Gardner J.P., Zhang F., Uskokovic M.R., Studzinski G.P. Vitamin D analog 25-(OH)-16,23E-diene-26,27-hexafluoro-vitamin D3 induces differentiation of HL60 cells with minimal effects on cellular calcium homeostasis. J. Cell Biochem. 1996, 63:500-512.
66. Peleg S., Liu Y.Y., Reddy S., Horst R.L., White M.C., Posner G.H. A 20-epi side chain restores growth-regulatory and transcriptional activities of an A ring-modified hybrid analog of 1 alpha, 25-dihydroxyvitamin D3 without increasing its affinity to the vitamin D receptor. J. Cell Biochem. 1996, 63:149-161.
67. Ritter C.S., Armbrecht H.J., Slatopolsky E., Brown A.J. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney. Int. 2006, 70:654-659.
68. Urushino N., Nakabayashi S., Arai M.A., Kittaka A., Chen T.C., Yamamoto K., et al. Kinetic studies of 25-hydroxy-19-nor-vitamin D3 and 1 alpha,25-dihydroxy-19-nor-vitamin D3 hydroxylation by CYP27B1 and CYP24A1. Drug. Metab. Dispos. 2007, 35:1482-1488.
69. Verstuyf A., Verlinden L., Van Baelen H., Sabbe K., D'Hallewyn C., De Clercq P., et al. The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C- and D-rings. J. Bone Min. Res. 1998, 13:549-558.
70. Binderup L., Latini S., Binderup E., Bretting C., Calverley M., Hansen K. 20-Epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem. Pharmacol. 1991, 42:1569-1575.
71. Elstner E., Heber D., Koeffler Hp 20-Epi-vitamin D3 analogs. Potent modulators of proliferation and differentiation of breast cancer cell lines in vitro. Adv. Exp. Med. Biol. 1996, 399:53-70.
72. Ryhanen S., Mahonen A., Jaaskelainen T., Maenpaa P.H. Synthetic 20-epi analogs of calcitriol are potent inducers of target-gene activation in osteoblastic cells. Eur. J. Biochem. 1996, 238:97-103.
73. Peleg S., Sastry M., Collins E.D., Bishop J.E., Norman A.W. Distinct conformational changes induced by 20-epi analogues of 1 alpha,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor. J. Biol. Chem. 1995, 270:10551-10558.
74. Vaisanen S., Ryhanen S., Saarela J.T., Maenpaa P.H. Structure-function studies of new C-20 epimer pairs of vitamin D3 analogs. Eur. J. Biochem. 1999, 261:706-713.
75. Sicinska W., Rotkiewicz P. Structural changes of vitamin D receptor induced by 20-epi-1alpha,25-(OH)2D3: an insight from a computational analysis. J. Steroid. Biochem. Mol. Biol. 2009, 113:253-258.
76. Dilworth F.J., Calverley M.J., Makin H.L., Jones G. Increased biological activity of 20-epi-1,25-dihydroxyvitamin D3 is due to reduced catabolism and altered protein binding. Biochem. Pharmacol. 1994, 47:987-993.
77. Siu-Caldera M.L., Sekimoto H., Peleg S., Nguyen C., Kissmeyer A.M., Binderup L., et al. Enhanced biological activity of 1alpha,25-dihydroxy-20-epi-vitamin D3, the C-20 epimer of 1alpha,25-dihydroxyvitamin D3, is in part due to its metabolism into stable intermediary metabolites with significant biological activity. J. Steroid Biochem. Mol. Biol. 1999, 71:111-121.
78. 3 into new metabolites with significant biological activity: studies in rat osteosarcoma cells (UMR 106 and ROS 17/2). J. Cell Biochem. 2001, 82:599-609.
79. Zella L.A., Meyer M.B., Nerenz R.D., Pike J.W. The enhanced hypercalcemic response to 20-epi-1,25-dihydroxyvitamin D3 results from a selective and prolonged induction of intestinal calcium-regulating genes. Endocrinology 2009, 150:3448-3456.
80. Jaaskelainen T., Ryhanen S., Mahonen A., DeLuca H.F., Maenpaa P.H. Mechanism of action of superactive vitamin D analogs through regulated receptor degradation. J. Cell Biochem. 2000, 76:548-558.
81. van den Bemd G.C., Pols H.A., Birkenhager J.C., van Leeuwen J.P. Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060. Proc. Natl. Acad. Sci. USA 1996, 93:10685-10690.
82. Yang W., Freedman L.P. 20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor. J. Biol. Chem. 1999, 274:16838-16845.
83. Issa L.L., Leong G.M., Sutherland R.L., Eisman J.A. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J. Bone Min. Res. 2002, 17:879-890.
84. Tocchini-Valentini G., Rochel N., Wurtz J.M., Mitschler A., Moras D. Crystal stuctures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci. USA 2001, 98:5491-5496.
85. Koike N., Hayakawa N., Kumaki K., Stumpf W.E. In vivo dose-related receptor binding of the vitamin D analogue [3H]-1,25-dihydroxy-22-oxavitamin D3 (OCT) in rat parathyroid, kidney distal and proximal tubules, duodenum, and skin, studied by quantitative receptor autoradiography. J. Histochem. Cytochem. 1998, 46:1351-1358.
86. 3 analogues. Steroids 2001, 66:213-221.
87. Barsony J., McKoy W. Molybdate increases intracellular 3',5'-guanosine cyclic monophosphate and stabilizes vitamin D receptor association with tubulin-containing filaments. J. Biol. Chem. 1992, 267:24457-24465.
88. Kamimura S., Gallieni M., Zhong M., Beron W., Slatopolsky E., Dusso A. Microtubules mediate cellular 25-hydroxyvitamin D3 trafficking and the genomic response to 1,25-dihydroxyvitamin D3 in normal human monocytes. J. Biol. Chem. 1995, 270:22160-22166.
89. Racz A., Barsony J. Hormone-dependent translocation of vitamin D receptors is linked to transactivation. J. Biol. Chem. 1999, 274:19352-19360.
90. McDonnell D.P., Scott R.A., Kerner Sa, BW O.M., Pike J.W. Functional domains of the human vitamin D3 receptor regulate osteocalcin gene expression. Mol. Endocrinol. 1989, 3:635-644.
91. Hsieh J.C., Jurutka P.W., Galligan M.A., Terpening C.M., Haussler C.A., Samuels D.S., et al. Human vitamin D receptor is selectively phosphorylated by protein kinase C on serine 51, a residue crucial to its trans-activation function. Proc. Natl. Acad. Sci. USA 1991, 88:9315-9319.
92. Yu X.P., Mocharla H., Hustmyer F.G., Manolagas S.C. Vitamin D receptor expression in human lymphocytes. Signal requirements and characterization by western blots and DNA sequencing. J. Biol. Chem. 1991, 266:7588-7595.
93. Krishnan A.V., Feldman D. Activation of protein kinase-C inhibits vitamin D receptor gene expression. Mol. Endocrinol. 1991, 5:605-612.
94. Jurutka P.W., Hsieh J.C., MacDonald P.N., Terpening C.M., Haussler C.A., Haussler M.R., et al. Phosphorylation of serine 208 in the human vitamin D receptor. The predominant amino acid phosphorylated by casein kinase II, in vitro, and identification as a significant phosphorylation site in intact cells. J. Biol. Chem. 1993, 268:6791-6799.
95. Darwish H.M., Burmester J.K., Moss V.E., DeLuca H.F. Phosphorylation is involved in transcriptional activation by the 1,25-dihydroxyvitamin D3 receptor. Biochim. Biophys. Acta 1993, 1167:29-36.
96. Matkovits T., Christakos S. Ligand occupancy is not required for vitamin D receptor and retinoid receptor-mediated transcriptional activation. Mol. Endocrinol. 1995, 9:232-242.
97. Nakajima S., Yamagata M., Sakai N., Ozono K. Effect of cyclic adenosine 3',5'-monophosphate and protein kinase A on ligand-dependent transactivation via the vitamin D receptor. Mol. Cell Endocrinol. 2000, 159:45-51.
98. Jurutka P.W., Terpening C.M., Haussler M.R. The 1,25-dihydroxy-vitamin D3 receptor is phosphorylated in response to 1,25-dihydroxy-vitamin D3 and 22-oxacalcitriol in rat osteoblasts, and by casein kinase II, in vitro. Biochemistry 1993, 32:8184-8192.
99. Jurutka P.W., MacDonald P.N., Nakajima S., Hsieh J.C., Thompson P.D., Whitfield G.K., et al. Isolation of baculovirus-expressed human vitamin D receptor: DNA responsivene element interactions and phosphorylation of the purified receptor. J. Cell. Biochem. 2002, 85:435-457.
100. Barletta F., Freedman L.P., Christakos S. Enhancement of VDR-mediated transcription by phosphorylation: correlation with increased interaction between the VDR and DRIP205, a subunit of the VDR-interacting protein coactivator complex. Mol. Endocrinol. 2002, 16:301-314.
101. 3 correlates with tyrosine phosphorylation of the vitamin D receptor (VDR) and VDR-Src interaction. J. Cell Biochem. 2000, 79:274-281.
102. Chen S., Wu J., Hsieh J.C., Whitfield G.K., Jurutka P.W., Haussler M.R., et al. Suppression of ANP gene transcription by liganded vitamin D receptor: involvement of specific receptor domains. Hypertension 1998, 31:1338-1342.
103. 3 and its 20-epi analog. Steroids 2001, 66:203-212.
104. Koszewski N.J., Reinhardt T.A., Horst R.L. Differential effects of 20-epi vitamin D analogs on the vitamin D receptor homodimer. J. Bone Min. Res. 1999, 14:509-517.
105. Carlberg C., Seuter S. A genomic perspective on vitamin D signaling. Anticancer. Res. 2009, 29:3485-3493.
106. M.B. Meyer, P.D. Goetsch, J.W. Pike, Genome-wide analysis of the VDR/RXR cistrome in osteoblast cells provides new mechanistic insight into the actions of the vitamin D hormone. J. Steroid Biochem. Mol. Biol. 121 (1-2) (2010) 136-141.
107. Schrader M., Kahlen J.P., Carlberg C. Functional characterization of a novel type of 1 alpha,25-dihydroxyvitamin D3 response element identified in the mouse c-fos promoter. Biochem. Biophys. Res. Commun. 1997, 230:646-651.
108. Liu Y.Y., Collins E.D., Norman A.W., Peleg S. Differential interaction of 1alpha,25-dihydroxyvitamin D3 analogues and their 20-epi homologues with the vitamin D receptor. J. Biol. Chem. 1997, 272:3336-3345.
109. Mathiasen I.S., Grue-Sorensen G., Hansen C.M., Binderup L., Bjorkling F. Studies on the interaction between the vitamin D receptor and the radiolabelled 20-epi vitamin D analogue GS 1500. Biochem. Biophys. Res. Commun. 1998, 250:283-286.
110. Lewin E., Olgaard K. The in vivo effect of a new, in vitro, extremely potent vitamin D3 analog KH1060 on the suppression of renal allograft rejection in the rat. Calcif. Tissue Int. 1994, 54:150-154.
111. Danielsson C., Nayeri S., Wiesinger H., Thieroff-Ekerdt R., Carlberg C. Potent gene regulatory and antiproliferative activities of 20-methyl analogues of 1,25 dihydroxyvitamin D3. J. Cell. Biochem. 1996, 63:199-206.
112. Danielsson C., Mathiasen I.S., James S.Y., Nayeri S., Bretting C., Hansen C.M., et al. Sensitive induction of apoptosis in breast cancer cells by a novel 1,25-dihydroxyvitamin D3 analogue shows relation to promoter selectivity. J. Cell Biochem. 1997, 66:552-562.
113. Liu Y.Y., Nguyen C., Peleg S. Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor. Mol. Endocrinol. 2000, 14:1776-1787.
114. Masuyama H., Brownfield C.M., St-Arnaud R., MacDonald P.N. Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol. Endocrinol. 1997, 11:1507-1517.
115. Schwinn M.K., DeLuca H.F. Differential recruitment of coactivators to the vitamin D receptor transcriptional complex by 1alpha,25-dihydroxyvitamin D3 analogs. Arch. Biochem. Biophys. 2007, 465:443-451.
116. Yamamoto H., Shevde N.K., Warrier A., Plum L.A., DeLuca H.F., Pike J.W. 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J. Biol. Chem. 2003, 278:31756-31765.
117. Takeyama K., Masuhiro Y., Fuse H., Endoh H., Murayama A., Kitanaka S., et al. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol. Cell Biol. 1999, 19:1049-1055.
118. Eelen G., Verlinden L., Rochel N., Claessens F., De Clercq P., Vandewalle M., et al. Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction. Mol. Pharmacol. 2005, 67:1566-1573.
119. Eelen G., Valle N., Sato Y., Rochel N., Verlinden L., De Clercq P., et al. Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor. Chem. Biol. 2008, 15:1029-1034.
120. Gonzalez M.M., Samenfeld P., Perakyla M., Carlberg C. Corepressor excess shifts the two-side chain vitamin D analog Gemini from an agonist to an inverse agonist of the vitamin D receptor. Mol. Endocrinol. 2003, 17:2028-2038.
121. Masuyama H., Dowd D., Brown A.J., Mac Donald P.N. Proteasome-mediated degradation of the vitamin D receptor (VDR) and the potential involvement of a 1,25(OH)2D3 dependent interaction between the vdr AF-2 domain and SUG1. J. Bone Min. Res. 1997, 12:S122.
122. Zhou Z.-X., Lane M.V., Kemppainen J.A., French F.S., Wilson E.M. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol. Endocrinol. 1995, 9:208-218.
123. Peleg S., Nguyen C., Woodard B.T., Lee J.K., Posner G.H. Differential use of transcription activation function 2 domain of the vitamin D receptor by 1,25-dihydroxyvitamin D3 and its A ring-modified analogs. Mol. Endocrinol. 1998, 12:525-535.
124. Fan J., Liu S., Du Y., Morrison J., Shipman R., Pang K.S. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. J. Pharmacol. Exp. Ther. 2009, 330:389-402.
125. Wu-Wong J.R., Nakane M., Ma J., Ruan X., Kroeger P.E. Effects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006, 186:20-28.
126. Vanoirbeek E., Eelen G., Verlinden L., Marchal K., Engelen K., De Moor B., et al. Microarray analysis of MCF-7 breast cancer cells treated with 1,25-dihydroxyvitamin D3 or a 17-methyl-D-ring analog. Anticancer. Res. 2009, 29:3585-3590.
127. Kriebitzsch C., Verlinden L., Eelen G., Tan B.K., Van Camp M., Bouillon R., et al. The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells - a microarray approach. Anticancer. Res. 2009, 29:3471-3483.
128. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 1995, 16:200-257.
129. Fujishima T., Konno K., Nakagawa K., Kurobe M., Okano T., Takayama H. Efficient synthesis and biological evaluation of all A-ring diastereomers of 1alpha,25-dihydroxyvitamin D3 and its 20-epimer. Bioorg. Med. Chem. 2000, 8:123-134.
130. 3. J. Nutr. Sci. Vitaminol. 1989, 35:529-533.
131. Kobayashi T., Okano T., Tsugawa N., Masuda S., Takeuchi A., Nishii Y. Metabolism and transporting system of 22-oxacalcitriol. Contrib. Nephrol. 1991, 91:129-133.
132. Brown A.J., Finch J., Grieff M., Ritter C., Kubodera N., Nishii Y., et al. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993, 133:1158-1164.
133. Brown A.J., Finch J.L., Lopez-Hilker S., Dusso A., Ritter C., Pernalete N., et al. New active analogues of vitamin D with low calcemic activity. Kidney. Int. 1990, 29(Suppl. 29):S22-27.
134. 3, determined by micro-autoradiography. Nephol. Dial. Transplant. 2002, 17(Suppl. 10):53-57.
135. Boehm M.F., Fitzgerald P., Zou A., Elgort M.G., Bischoff E.D., Mere L., et al. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem. Biol. 1999, 6:265-275.
136. Okano T., Tsugawa N., Masuda S., Takeuchi A., Kobayashi T., Nishii Y. A novel synthetic vitamin D3 analogue, 2-beta-(3-hydroxypropoxy)-calcitriol (ED-71): its biological activities and pharmacological effects on calcium metabolism. Contrib. Nephrol. 1991, 91:116-122.
137. Okano T., Tsugawa N., Masuda S., Takeuchi A., Kobayashi T., Takita Y., et al. Regulatory activities of 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem. Biophys. Res. Commun. 1989, 163:1444-1449.
138. Zella L.A., Shevde N.K., Hollis B.W., Cooke N.E., Pike J.W. Vitamin D-binding protein influences total circulating levels of 1,25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology 2008, 149:3656-3667.
139. Dusso A.S., Negrea L., Gunawardhana S., Lopez-Hilker S., Finch J., Mori T., et al. On the mechanisms for the selective action of vitamin D analogs. Endocrinology 1991, 128:1687-1692.
140. Bouillon R., Allewaert K., Xiang D.Z., Tan B.K., van Baelen H. Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity. J. Bone Min. Res. 1991, 6:1051-1057.
141. 3, in rats. J. Biochem. 1994, 115:373-380.
142. Teramoto T., Endo K., Ikeda K., Kubodera N., Kinoshita M., Yamanaka M., et al. Binding of vitamin D to low-density-lipoprotein (LDL) and LDL receptor-mediated pathway into cells. Biochem. Biophys. Res. Commun. 1995, 215:199-204.
143. Haddad J.G., Jennings A.S., Aw T.C. Vitamin D uptake and metabolism by perfused rat liver: influences of carrier proteins. Endocrinology 1988, 123:498-504.
144. Haddad J.G., Aden D.P., Aw T.C. Plasma carriers influence the uptake of cholecalciferol by human hepatoma-derived cells. J. Bone Min. Res. 1989, 4:243-247.
145. Keenan M.J., Holmes R.P. The uptake and metabolism of 25-hydroxyvitamin D3 and vitamin D binding protein by cultured porcine kidney cells (LLC-PK1). Int. J. Biochem. 1991, 23:1225-1230.
146. Esteban C., Geuskens M., Ena J.M., Mishal Z., Macho A., Torres J.M., et al. Receptor-mediated uptake and processing of vitamin D-binding protein in human B-lymphoid cells. J. Biol. Chem. 1992, 267:10177-10183.
147. Stewart P.M., Shappard M.C. Novel aspects of hormone action: intracellular ligand supply and its control by a series of tissue-specific enzymes. Mol. Cell Endocrinol. 1992, 83:C13-C18.
148. Zhao J., Tan B.K., Marcelis S., Verstuyf A., Bouillon R. Enhancement of antiproliferative activity of 1alpha,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific. J. Steroid Biochem. Mol. Biol. 1996, 57:197-202.
149. Shankar V.N., Dilworth F.J., Makin H.L., Schroeder N.J., Trafford D.J., Kissmeyer A.M., et al. Metabolism of the vitamin D analog EB 1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain. Biochem. Pharmacol. 1997, 53:783-793. [published erratum appears in Biochem. Pharmacol. 53 (12) (1997) (1946)].
150. Hansen C.M., Maenpaa P.H. EB1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells. Biochem. Pharmacol. 1997, 54:1173-1179.
151. Kissmeyer A.M., Binderup E., Binderup L., Mork Hansen C., Andersen N.R., Makin H.L., et al. Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. Biochem. Pharmacol. 1997, 53:1087-1097.
152. 3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 2002, 16:1243-1256.
153. Brown A.J., Berkoben M., Ritter C., Kubodera N., Nishii Y., Slatopolsky E. Metabolism of 22-oxacalcitriol by a vitamin D-inducible pathway in cultured parathyroid cells. Biochem. Biophys. Res. Commun. 1992, 189:759-764.
154. Bikle D.D., Abe-Hashimoto J., Su M.J., Felt S., Gibson D.F., Pillai S. 22-Oxa calcitriol is a less potent regulator of keratinocyte proliferation and differentiation due to decreased cellular uptake and enhanced catabolism. J. Invest. Dermatol. 1995, 105:693-698.
155. Kamimura S., Gallieni M., Kubodera N., Nishii Y., Brown A.J., Slatopolsky E., et al. Differential catabolism of 22-oxacalcitriol and 1,25-dihydroxyvitamin D3 by normal human peripheral monocytes. Endocrinology 1993, 133:2719-2723.
156. Reddy G.S., Clark J.W., Tserng K.Y., Uskokovic M.R., McLane J.A. Metabolism of 1,25(OH)2-16-ene-D3 in kidney: influence of structural modification of D-ring on side chain metabolism. Bioorg. Med. Chem. Lett. 1993, 3:1879-1884.
157. Siu-Caldera M.L., Clark J.W., Santos-Moore A., Peleg S., Liu Y.Y., Uskokovic M.R., et al. 1Alpha,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1alpha,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells. J. Steroid Biochem. Mol. Biol. 1996, 59:405-412.
158. Dilworth F.J., Williams G.R., Kissmeyer A.M., Nielsen J.L., Binderup E., Calverley M.J., et al. The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology 1997, 138:5485-5496.
159. 3 (KH1060) to the overall biological activity of KH1060 by a shared mechanism of action. Biochem. Pharmacol. 2000, 59:621-627.
160. 3 in the bones of rats dosed with tritium-labeled compounds. Steroids 1998, 63:505-510.
161. Komuro S., Sato M., Kanamaru H. Disposition and metabolism of F6-1alpha,25(OH)2 vitamin D3 and 1alpha,25(OH)2 vitamin D3 in the parathyroid glands of rats dosed with tritium-labeled compounds. Drug. Metab. Dispos. 2003, 31:973-978.
162. Laverny G., Penna G., Uskokovic M., Marczak S., Maehr H., Jankowski P., et al. Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3. J. Med. Chem. 2009, 52:2204-2213.
163. Flanagan J.N., Zheng S., Chiang K.C., Kittaka A., Sakaki T., Nakabayashi S., et al. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer. Res. 2009, 29:3547-3553.
164. Saito N., Suhara Y., Abe D., Kusudo T., Ohta M., Yasuda K., et al. Synthesis of 2alpha-propoxy-1alpha,25-dihydroxyvitamin D3 and comparison of its metabolism by human CYP24A1 and rat CYP24A1. Bioorg. Med. Chem. 2009, 17:4296-4301.
165. Shimizu M., Miyamoto Y., Kobayashi E., Shimazaki M., Yamamoto K., Reischl W., et al. Synthesis and biological activities of new 1alpha,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain. Bioorg. Med. Chem. 2006, 14:4277-4294.
166. Glebocka A., Sicinski R.R., Plum L.A., Clagett-Dame M., DeLuca H.F. New 2-alkylidene 1alpha,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxypropylidene) derivatives. J. Med. Chem. 2006, 49:2909-2920.
167. Kobayashi E., Shimazaki M., Miyamoto Y., Masuno H., Yamamoto K., DeLuca H.F., et al. Structure-activity relationships of 19-norvitamin D analogs having a fluoroethylidene group at the C-2 position. Bioorg. Med. Chem. 2007, 15:1475-1482.
168. Glebocka A., Sicinski R.R., Plum L.A., DeLuca H.F. 2-(3'-Hydroxypropylidene)-1alpha-hydroxy-19-norvitamin D compounds with truncated side chains. J. Steroid. Biochem. Mol. Biol. 2007, 103:310-315.
169. Ritter C.S., Brown A.J. Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D binding protein and resistance to metabolism. J. Cell. Biochem. 2011, in press.
170. Lechner D., Manhardt T., Bajna E., Posner G.H., Cross H.S. A 24-phenylsulfone analog of vitamin D inhibits 1alpha,25-dihydroxyvitamin D(3) degradation in vitamin D metabolism-competent cells. J. Pharmacol. Exp. Ther. 2007, 320:1119-1126.
171. Sekimoto H., Siu-Caldera M.L., Weiskopf A., Vouros P., Muralidharan K.R., Okamura W.H., et al. 1Alpha,25-dihydroxy-3-epi-vitamin D3: in vivo metabolite of 1alpha,25-dihydroxyvitamin D3 in rats. FEBS. Lett. 1999, 448:278-282.
172. Brown A.J., Ritter C., Slatopolsky E., Muralidharan K.R., Okamura W.H., Reddy G.S. 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion. J. Cell Biochem. 1999, 73:106-113.
173. Kamao M., Tatematsu S., Hatakeyama S., Ozono K., Kubodera N., Reddy G.S., et al. Two novel metabolic pathways of 22-oxacalcitriol (OCT). C-25 dehydration and C-3 epimerization and biological activities of novel OCT metabolites. J. Biol. Chem. 2003, 278:1463-1471.
174. 3 that resist metabolism through the C-24 oxidation pathway are metabolized through the C-3 epimerization pathway. Arch. Biochem. Biophys. 2000, 383:197-205.
175. Khanal R., Nemere I. Membrane receptors for vitamin D metabolites. Crit. Rev. Eukaryot. Gene. Expr. 2007, 17:31-47.
176. Nemere I., Yoshimoto Y., Norman A.W. Calcium transport in perfused duodena from normal chicks: enhancement within fourteen minutes of exposure to 1,25-dihydroxyvitamin D3. Endocrinology 1984, 115:1476-1483.
177. 3-stimulated Egr induction. J. Biol. Chem. 1995, 270:3642-3647.
178. 3 in promyelocytic NB4 leukemic cells: a structure-function study. Endocrinology 1998, 139:457-465.
179. Zanello L.P., Norman A.W. 1 Alpha,25(OH)2 vitamin D3-mediated stimulation of outward anionic currents in osteoblast-like ROS 17/2.8 cells. Biochem. Biophys. Res. Commun. 1996, 225:551-556.
180. Lieberherr M., Grosse B., Duchambon P., Drueke T. A functional cell surface type receptor is required for the early action of 1,25-dihydroxyvitamin D3 on the phosphoinositide metabolism in rat enterocytes. J. Biol. Chem. 1989, 264:20403-20406.
181. Zhou L.X., Nemere I., Norman A.W. 1,25-Dihydroxyvitamin D3 analog structure-function assessment of the rapid stimulation of intestinal calcium absorption (transcaltachia). J. Bone Min. Res. 1992, 7:457-463.
182. Norman A.W., Song X., Zanello L., Bula C., Okamura W.H. Rapid and genomic biological responses are mediated by different shapes of the agonist steroid hormone, 1alpha,25(OH)2vitamin D3. Steroids 1999, 64:120-128.
183. Farach-Carson M.C., Abe J., Nishii Y., Khoury R., Wright G.C., Norman A.W. 22-Oxacalcitriol: dissection of 1,25(OH)2D3 receptor-mediated and Ca2+ entry-stimulating pathways. Am. J. Physiol. 1993, 265:F705-711.
184. Mizwicki M.T., Bishop J.E., Norman A.W. Applications of the vitamin D sterol-vitamin D receptor (VDR) conformational ensemble model. Steroids 2005, 70:464-471.
185. Nemere I., Dormanen M.C., Hammond M.W., Okamura W.H., Norman A.W. Identification of a specific binding protein for 1 alpha,25-dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J. Biol. Chem. 1994, 269:23750-23756.
186. 3 which mediates the rapid activation of protein kinase C. J. Bone Min. Res. 1998, 13:1353-1359.
187. Boyan B.D., Dean D.D., Sylvia V.L., Schwartz Z. Nongenomic regulation of extracellular matrix events by vitamin D metabolites. J. Cell Biochem. 1994, 56:331-339.
188. Baran D.T. Nongenomic actions of the steroid hormone 1 alpha,25-dihydroxyvitamin D3. J. Cell Biochem. 1994, 56:303-306.
189. Baran D.T., Sorensen A.M., Shalhoub V., Owen T., Stein G., Lian J. The rapid nongenomic actions of 1 alpha,25-dihydroxyvitamin D3 modulate the hormone-induced increments in osteocalcin gene transcription in osteoblast-like cells. J. Cell Biochem. 1992, 50:124-129.
190. Khoury R., Ridall A.L., Norman A.W., Farach-Carson M.C. Target gene activation by 1,25-dihydroxyvitamin D3 in osteosarcoma cells is independent of calcium influx. Endocrinology 1994, 135:2446-2453.
191. Khoury R.S., Weber J., Farach-Carson M.C. Vitamin D metabolites modulate osteoblast activity by Ca+2 influx-independent genomic and Ca+2 influx-dependent nongenomic pathways. J. Nutr. 1995, 125:1699S-1703S.
192. Norman A.W., Bouillon R., Farach-Carson M.C., Bishop J.E., Zhou L.X., Nemere I., et al. Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3. J. Biol. Chem. 1993, 268:20022-20030.
193. Zhou L.X., Norman A.W. 1 Alpha,25(OH)2-vitamin D3 analog structure-function assessment of intestinal nuclear receptor occupancy with induction of calbindin-D28K. Endocrinology 1995, 136:1145-1152.
194. Hedlund T.E., Moffatt K.A., Miller G.J. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 1996, 137:1554-1561.
195. Richard C.L., Farach-Carson M.C., Rohe B., Nemere I., Meckling K.A. Involvement of 1,25D3-MARRS (membrane associated, rapid response steroid-binding), a novel vitamin D receptor, in growth inhibition of breast cancer cells. Exp. Cell Res. 2010, 316:695-703.
196. Safran J.B., Butler W.T., Farach-Carson M.C. Modulation of osteopontin post-translational state by 1,25-(OH)2-vitamin D3. Dependence on Ca2+ influx. J. Biol. Chem. 1998, 273:29935-29941.
197. Gacad M.A., Adams J.S. Endogenous blockade of 1,25-dihydroxyvitamin D-receptor binding in New World primate cells. J. Clin. Invest. 1991, 87:996-1001.
198. Gacad M.A., Adams J.S. Specificity of steroid binding in New World primate B95-8 cells with a vitamin D-resistant phenotype. Endocrinology 1992, 131:2581-2587.
199. Gacad M.A., Adams J.S. Identification of a competitive binding component in vitamin D-resistant New World primate cells with a low affinity but high capacity for 1,25-dihydroxyvitamin D3. J. Bone Min. Res. 1993, 8:27-35.
200. Gacad M.A., Chen H., Arbelle J.E., LeBon T., Adams J.S. Functional characterization and purification of an intracellular vitamin D-binding protein in vitamin D-resistant new world primate cells. Amino acid sequence homology with proteins in the hsp-70 family. J. Biol. Chem. 1997, 272:8433-8440.
201. Gacad M.A., Adams J.S. Proteins in the heat shock-70 family specifically bind 25-hydroxyvitamin D3 and 17beta-estradiol. J. Clin. Endocrinol. Metab. 1998, 83:1264-1267.
202. Wu S., Ren S., Chen H., Chun R.F., Gacad M.A., Adams J.S. Intracellular vitamin D binding proteins: novel facilitators of vitamin D-directed transactivation. Mol. Endocrinol. 2000, 14:1387-1397.
203. Wu S., Chun R.F., Gacad M.A., Ren S., Chen H., Adams J.S. Regulation of 1,25-dihydroxyvitamin D synthesis by intracellular vitamin D binding protein-1. Endocrinology 2002, 143:4135-4138.
204. Adams J.S., Chen H., Chun R.F., Nguyen L., Wu S., Ren S.Y., et al. Novel regulators of vitamin D action and metabolism: lessons learned at the Los Angeles zoo. J. Cell Biochem. 2003, 88:308-314.
205. Chun R.F., Gacad M., Nguyen L., Hewison M., Adams J.S. Co-chaperone potentiation of vitamin D receptor-mediated transactivation: a role for Bcl2-associated athanogene-1 as an intracellular-binding protein for 1,25-dihydroxyvitamin D3. J. Mol. Endocrinol. 2007, 39:81-89.
206. Krishnan A.V., Srinivas S., Feldman D. Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermatoendocrinol. 2009, 1:7-11.
207. Aparna R., Subhashini J., Roy K.R., Reddy G.S., Robinson M., Uskokovic M.R., et al. Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. J. Cell Biochem. 2008, 104:1832-1842.